WITHUS PHARMACEUTICALLTD Valuation
Is A330350 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of A330350 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von A330350 für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von A330350 für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A330350?
Other financial metrics that can be useful for relative valuation.
| What is A330350's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | ₩113.93b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.5x |
| Enterprise Value/EBITDA | 11.4x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does A330350's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 13.8x | ||
A106190 High Tech Pharm | 13x | n/a | ₩104.9b |
A066700 Theragen EtexLtd | 4.8x | n/a | ₩133.6b |
A002800 Sinsin Pharmaceutical | 19.9x | n/a | ₩93.0b |
A004720 PharmGen Science | 17.5x | n/a | ₩100.5b |
A330350 WITHUS PHARMACEUTICALLTD | 14.3x | n/a | ₩113.9b |
Price-To-Earnings gegen Gleichaltrige: A330350 ist auf der Grundlage des Price-To-Earnings Verhältnisses (14.5x) im Vergleich zum Durchschnitt der Vergleichsgruppe (13x) teuer.
Price to Earnings Ratio vs Industry
How does A330350's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?
Price-To-Earnings gegen Industrie: A330350 ist aufgrund seines Price-To-Earnings Verhältnisses (15.2x) im Vergleich zum KR Pharmaceuticals Branchendurchschnitt (21.5x) ein guter Wert.
Price to Earnings Ratio vs Fair Ratio
What is A330350's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 14.3x |
| Fair PE Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Earnings Fair Ratio von A330350 für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.